SpicyIP

JULY 8, 2024

Here is our recap of last week’s top IP developments including summary of the posts on the DHC’s direction to frame a code of conduct for Patent and Trademark Agents, MHC’s decision on prior arts, and the settlement between Dabur and Dhruv Rathee of their trademark and copyright dispute. Anything we are missing out on?

Invention 59

Invention Art Trademark Patent Application 59

Biswajit Sarkar Copyright Blog

DECEMBER 19, 2023

As India aims for a $5 trillion economy, the MSME ministry sets ambitious goals, aiming to elevate their GDP contribution by up to 50% by 2025. With the enactment of the MSME Act,2006; an effective mechanism has emerged, enhancing the MSME claim settlement procedure and striving to make it more accessible.

Settlement 52

Settlement Intellectual Property Registration Designs 52

The IPKat

FEBRUARY 29, 2024

This is an interesting legal question as the Copyright, Designs and Patents Act 1988 (the CDPA) brought in new performers’ rights, even for earlier performances such as Mitchell’s and Redding’s subject to transitional provisions regarding prior contracts. The wider context of this case is an industry where “catalogue” (i.e.

Copyright 107

Copyright Reporting Contracts Settlement 107

LexBlog IP

JANUARY 25, 2024

The approval of Amgen’s WEZLANA (ustekinumab-auub) as biosimilar to Janssen’s STELARA (ustekinumab) is noteworthy given that it received designation as interchangeable. According to a reported statement from Amgen, its settlement agreement with Janssen allows Amgen to sell WEZLANA “no later than January 1, 2025.”

Marketing 52

Marketing Marketing Licensing Litigation 52

Fish & Richardson Trademark & Copyright Thoughts

FEBRUARY 4, 2021

The biosimilar pathway was designed to increase competition for biologics and reduce healthcare costs. Note that FDA still has not designated any biosimilar as interchangeable to its reference product. No earlier than July 31, 2023 per settlement. No earlier than November 20, 2023 per settlement. . Introduction.

Litigation 52

Litigation Settlement Marketing Marketing 52

Patently-O

MAY 15, 2024

This wave of RFCs includes significant proposals aimed at adjusting patent fees for fiscal year 2025, refining terminal disclaimer practices, and addressing the impact of artificial intelligence on prior art and patentability. 325(d) considerations, parallel and serial petitions, and settlement-related terminations.

Art 44

Art Intellectual Property Designs Design 44